Synthetic investigation on chirally pure Mannich derivatives of pseudophenylpropanolamine and their anticancer properties against HepG-2 cells with inhibition of JAK2/STAT3Electronic supplementary information (ESI) available. CCDC 1443803. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c6ra22480f
A novel series of Mannich derivatives of 3a-g and 3a′-g′ were designed and synthesized from pseudophenylpropanolamine (Ψ-PPA). The stereo chemical aspects of the synthesized compounds were studied and all compounds were well characterized with respect to spectral techniques. All Mannich derivatives,...
Gespeichert in:
Hauptverfasser: | , , , , , , , , |
---|---|
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | A novel series of Mannich derivatives of
3a-g
and
3a′-g′
were designed and synthesized from pseudophenylpropanolamine (Ψ-PPA). The stereo chemical aspects of the synthesized compounds were studied and all compounds were well characterized with respect to spectral techniques. All Mannich derivatives,
3a-g
and
3a′-g′
were evaluated for their anti-proliferative activity against A549 and HepG-2 cells. Among the tested compounds,
3a
showed significant anti-proliferative activity against HepG-2 cells at 25 μM when compared to other compounds. The treatment of
3a
exhibited morphological changes, nuclear condensation, colony formatting ability, apoptosis and cell cycle arrest at G2/M phase in HepG-2 cells. Besides,
3a
triggered mitochondrial mediated apoptotic pathway as indicated by down regulation of Bcl-2, up-regulation of Bax, and release of cytochrome
c
and caspases-3. Furthermore,
3a
effectively suppressed the cell proliferation and cell growth
via
JAK2/STAT3 signaling pathway in a time and dose dependent manner.
In vivo
administration of
3a
inhibited tumor growth without significant change in body weight in HepG-2 xenograft mice model. Molecular docking studies revealed that good binding energies of compound
3a
against JAK2 (−6.10 kcal mol
−1
) and Bcl-2 (−6.04 kcal mol
−1
) receptors. Taken together,
3a
possessed potent antitumor activity; it could be a promising lead candidate for the potential treatment of human hepatocellular carcinoma.
In vitro
and
in vivo
anticancer activity of compound
3a
was proved as a novel blocker of JAK2/STAT3 signaling pathway and exerts both anti-proliferative and apoptotic activities in HepG-2 cells with xenograft mice model. |
---|---|
ISSN: | 2046-2069 |
DOI: | 10.1039/c6ra22480f |